Fractional CFO for Biotech & Life Sciences Companies
Biotech companies operate on different timelines and economics than typical startups. Years of R&D before revenue, complex funding structures, and regulatory milestones require specialized financial leadership.
Biotech finance is fundamentally different. You might spend a decade and hundreds of millions of dollars before generating a single dollar of product revenue. Traditional startup metrics don't apply, and a CFO without life sciences experience will struggle to provide meaningful guidance.
Whether you're a therapeutics company, a diagnostics startup, or a life sciences tools business, this guide explains what makes biotech finance unique and what to look for in financial leadership.
The Biotech Investment Landscape
Biotech remains one of the most capital-intensive sectors. Early-stage companies often raise $50-100M+ before reaching clinical proof-of-concept. Managing this capital efficiently while hitting scientific milestones is the core challenge.
Seed/Series A
$2-15M for discovery and pre-clinical
Series B
$30-80M for clinical trials
Series C+
$100M+ for late-stage trials
IPO/Acquisition
Exit or public markets
What Makes Biotech Finance Unique
Biotech financial management differs from other industries in fundamental ways:
Pre-Revenue for Years
Most biotech companies generate no product revenue for 5-10+ years. Burn management and runway extension are existential priorities.
Milestone-Driven Value
Company value is tied to scientific and regulatory milestones, not revenue. Each clinical phase transition can double or triple valuation.
Complex Funding Structures
Grants, venture debt, royalty financing, partnerships—biotech uses diverse capital sources with different terms and accounting treatment.
Binary Outcomes
Clinical trials either succeed or fail. Financial planning must account for both scenarios and their dramatically different implications.
Biotech Subsectors
| Subsector | Revenue Model | Key Financial Considerations |
|---|---|---|
| Therapeutics | Product sales, royalties, milestones | Long timelines, high burn, clinical trial costs |
| Diagnostics | Test revenue, per-test fees | Reimbursement, scale economics, CLIA compliance |
| Life Sciences Tools | Instrument sales, consumables, services | Razor/blade model, R&D spend, capital equipment |
| Contract Research (CRO) | Service fees, FTEs | Utilization, project accounting, capacity |
| Digital Therapeutics | Subscription, per-patient, outcomes | Software + clinical, reimbursement pathways |
Key Metrics for Biotech Companies
Biotech investors focus on different metrics than typical tech investors:
Financial Health Metrics
| Metric | Definition | Why It Matters |
|---|---|---|
| Cash Runway | Months of cash remaining | Existential metric; must exceed next milestone |
| Monthly Burn Rate | Net cash consumed per month | Determines funding needs and timing |
| R&D Spend | Total R&D investment | Core investment; often 70-90% of spend |
| G&A as % of Total | Administrative overhead ratio | Should be low; capital should go to science |
Program-Level Metrics
Cost per Program
Total spend allocated to each drug candidate or program. Essential for portfolio prioritization.
Time to Milestone
Months until next value-creating milestone. Drives fundraising timing and investor communication.
Clinical Trial Costs
Per-patient, per-site, and total trial costs. Often the largest single expense category.
FTE Efficiency
Progress per headcount. Biotech investors prefer lean teams that leverage external partners.
Runway to Next Milestone
The most important metric in biotech: do you have enough cash to reach your next value-creating milestone? Raising capital after a failed milestone is nearly impossible, while raising after success is done from a position of strength.
Funding & Capital Management
Biotech companies use diverse funding sources, each with unique characteristics:
Funding Sources
| Source | Typical Stage | Key Considerations |
|---|---|---|
| NIH/SBIR Grants | Early stage | Non-dilutive; complex compliance and reporting |
| Venture Capital | All stages | Dilutive; milestone-based tranches common |
| Venture Debt | Post-Series A | Extends runway; covenants and warrants |
| Pharma Partnerships | Clinical stage | Upfront, milestones, royalties; complex accounting |
| Royalty Financing | Late stage | Non-dilutive; trades future revenue for cash now |
| Public Markets (IPO) | Phase 2+ | Large capital access; public company requirements |
Grant Accounting Complexity
NIH/Federal Grants
Require strict cost allocation, effort reporting, and compliance with federal acquisition regulations. Indirect cost rates must be negotiated. Audit risk is real.
Revenue Recognition
Grant revenue is recognized as costs are incurred, not when cash is received. Deferred revenue and receivables require careful tracking.
Cost Allocation
Shared costs must be allocated appropriately across grants and internal programs. Incorrect allocation can result in clawbacks and debarment.
Clinical Development Finance
Clinical trials are typically the largest expense for therapeutics companies:
Clinical Trial Cost Drivers
| Cost Category | % of Trial Budget | Key Variables |
|---|---|---|
| Site Costs | 30-40% | Number of sites, geographic mix |
| Patient Recruitment | 15-25% | Indication, inclusion criteria, competition |
| Drug Manufacturing | 10-20% | Complexity, scale, comparator drugs |
| CRO/Vendor Fees | 15-25% | Scope, duration, change orders |
| Regulatory/Medical | 5-10% | Submissions, medical monitoring |
Common Financial Pitfalls
Underestimating Enrollment Time
Slow enrollment extends timelines and burns cash. Budget contingency for enrollment delays and rescue strategies.
Change Order Creep
CRO contracts often balloon 20-30% through change orders. Track and negotiate aggressively, and build contingency into budgets.
Manufacturing Delays
Drug supply issues can delay trials significantly. CMC (chemistry, manufacturing, controls) work should start early and be funded adequately.
Contingency Planning
Experienced biotech CFOs budget 15-25% contingency on clinical programs and plan for scenarios where trials take 50% longer than expected. The downside of running out of cash mid-trial is catastrophic.
What a Fractional CFO Does for Biotech Companies
A specialized biotech CFO provides:
Financial Planning & Runway Management
- Build detailed cash forecasts tied to program timelines
- Model scenarios for trial success, delays, and failures
- Plan fundraising timing to extend runway past key milestones
Grant & Partnership Accounting
- Manage NIH/SBIR grant compliance and reporting
- Properly account for partnership milestones and royalties
- Navigate complex revenue recognition requirements
Investor & Board Relations
- Prepare materials for biotech-focused investors
- Build board reporting around scientific and financial milestones
- Support due diligence for funding rounds
Program & Vendor Management
- Track costs by program for portfolio prioritization
- Negotiate and manage CRO and CMO contracts
- Build financial controls for clinical operations
When to Hire a Fractional CFO for Your Biotech
Consider fractional CFO support when:
Series A and Beyond
Institutional investors expect sophisticated financial management. Board reporting and cash management become critical.
Entering Clinical Trials
Clinical operations dramatically increase financial complexity. CRO contracts, patient costs, and regulatory expenses require oversight.
Grant Funding
Federal grants come with complex compliance requirements. Proper accounting and reporting prevent costly mistakes.
Partnership Discussions
Pharma partnerships involve complex deal structures. Financial modeling and negotiation support is valuable.
What to Look For
Biotech Experience
They should have worked with biotech companies and understand the unique timeline and economics.
Grant Expertise
Understanding of NIH/SBIR grants, compliance requirements, and federal cost accounting.
Clinical Trial Finance
Experience budgeting and tracking clinical programs, managing CRO relationships, and forecasting trial costs.
Life Sciences Investor Network
Familiarity with biotech VCs and what life sciences investors prioritize.
Related Articles
Fractional CFO Guide
Complete guide to fractional CFO services
Startup Runway Guide
Managing cash and extending runway
Series A Preparation
Get your finances investor-ready
Fractional CFO for Healthcare
Related healthcare industry insights
Biotech Financial Expertise
Eagle Rock CFO understands biotech's unique challenges. From grant management to clinical trial budgeting, we help life sciences companies manage their finances through every stage of development.
Get Free Cash Flow Analysis